Ontology highlight
ABSTRACT:
SUBMITTER: Rivera-Lebron BN
PROVIDER: S-EPMC5933647 | biostudies-literature | 2017 Jun
REPOSITORIES: biostudies-literature
Therapeutic advances in respiratory disease 20170420 6
Pulmonary arterial hypertension (PAH) is a progressive disease defined by an elevation in pulmonary arterial pressure that can lead to right heart failure and death. Ambrisentan is a selective endothelin receptor antagonist approved for the treatment of idiopathic, heritable PAH and connective tissue disease-associated PAH. Ambrisentan has been shown to improve exercise capacity and hemodynamics with an acceptable side-effect profile. It has also proven to be safely used in combination with othe ...[more]